Necrotizing enterocolitis (NEC), a serious multisystemic inflammatory disease most commonly seen in premature neonates, is often associated with thrombocytopenia. Infants with severe forms of NEC commonly have platelet counts of less than 50,000/mm 3 , occasionally less than 10,000/mm 3 . Despite an absence of data to support the practice, platelet transfusions are commonly used to maintain a certain arbitrary platelet count in an effort to prevent bleeding. As platelet transfusions contain a variety of bioactive factors including pro-inflammatory cytokines, we hypothesized that a higher number and volume of platelet transfusions would not be associated with an improvement in mortality or morbidity.
INTRODUCTION
Thrombocytopenia is a relatively common problem that occurs in 0. 5 to 6% of all neonates and 25% of neonates admitted to the NICU. [1] [2] [3] [4] Causes of early onset thrombocytopenia include maternal preeclampsia, birth asphyxia, immune-mediated thrombocytopenia (isoimmune or autoimmune), and early-onset sepsis. Causes of late-onset thrombocytopenia include sepsis and necrotizing enterocolitis (NEC). 3, 4 Many of the severe cases of NEC are associated with thrombocytopenia. In one study, a platelet count of <100,000/mm 3 was found to have an 89% positive predictive value for gut necrosis. 5 Thrombocytopenia has also been associated with an increased risk of mortality in NEC.
Platelet transfusions are generally performed in the presence of thrombocytopenia to prevent or treat bleeding, particularly intraventricular hemorrhage; however, despite the many guidelines suggested, no standard therapy exists. [8] [9] [10] Recent studies have failed to demonstrate consistent benefit to empiric platelet transfusion. 2, 8, 11 Inasmuch as there are no data in the literature regarding the benefit of platelet transfusions in NEC with thrombocytopenia, there are associated risks. As with any blood product transfusion, there are risks of hemolytic, febrile, and allergic reactions, 12, 13 as well as a significant risk of transmission of blood-borne pathogens, such as HIV, hepatitis B, hepatitis C, and bacteria through contamination of the blood component. [14] [15] [16] [17] Additionally, we theorized that transfusing platelets to an infant with NEC could exacerbate the disease by inadvertently infusing a variety of bioactive substances, including plasminogen activator inhibitor 1, histamine, myeloperoxidase, potentially damaging bioactive lipids, and platelet-activating factor (PAF), a key cytokine that plays a central role in NEC. [18] [19] [20] [21] [22] [23] As there are data that suggest that platelet transfusions are associated with an increased mortality, 11 we sought to determine whether the risk of mortality and morbidity (short bowel syndrome and cholestasis) was increased by the number and volume of platelet transfusions given to infants with NEC.
MATERIALS AND METHODS
After approval for the study by the Baylor College of Medicine Institutional Review Board for human subject research, infants at Texas Children's Hospital diagnosed with Bell's Stage 2 or 3 NEC between 1997 and 2001 were identified, and their clinical presentations and outcomes reviewed. Infants that met inclusion criteria were those with radiological findings (pneumatosis intestinalis or portal venous air) or pathological findings consistent with Bell's Stage 2 and 3 NEC. Infants who had incomplete medical records or whose clinical and/or surgical findings were consistent with an isolated, spontaneous perforation were excluded. Platelet counts of the infants were reviewed, and the subset of patients whose platelet counts within the first three days of NEC was <100,000/mm 3 formed the study population. Patients were divided into groups and compared based on outcome data. Specific outcomes included mortality (death before hospital discharge), short bowel syndrome (defined as need for TPN beyond 60 days), and presence or absence of cholestastatic liver disease (direct bilirubin >2.0 mg/dl in conjunction with an alkaline phosphatase >350 U/l). Information abstracted from the medical records included gestational age, birth weight, number of infants fed exclusively on breast milk (no formula administered), number of infants that received antenatal steroids, postnatal steroids or postnatal indomethacin, and number of infants that had an umbilical arterial catheter placed. The total number, total volume, and volume per kilogram per body weight of platelet transfusions were compared between the outcome groups.
Statistical analyses were performed using SPSS for Windows (SPSS Inc, version 12, Chicago, IL). Demographic data were compared using w 2 analysis with Fisher's exact test and the twotailed Student's t-test. Mean number and volume of platelet transfusions were compared using nonparametric tests. Differences were considered significant if the p-value was <0.05.
RESULTS
Of 147 infants given a diagnosis of NEC between 1997 and 2001, 46 patients met the inclusion criteria. Study patients were divided into groups and compared based on outcome data. The clinical characteristics of patients grouped by death as the study outcome are shown in Table 1 . A higher percentage of patients that died had received indomethacin postnatally, but all other clinical characteristics were similar between groups. The clinical characteristics of patient groups based on morbidity are shown in Table 2 . Although a higher proportion of infants fed formula had short bowel syndrome or cholestasis, other clinical characteristics were similar between groups.
There were a total of 406 platelet transfusions given to the study population. Of these, 151 (37.2%) were administered in the presence of active bleeding. Other indications for platelet transfusions included a platelet count below a set level desired by the attending physician (usually 20 to 50,000/mm 3 depending on the individual attending) or the presence of hypotension. The average change in platelet count after a platelet transfusion (typically recorded 6 to 24 hours after a transfusion) was 42,245±46,438/mm 3 (mean±SD; range: À3,750 to 229,000/mm 3 ). Average increases in platelet counts after platelet transfusions were not different between subgroups listed in Tables 1 and 2 respectively. Of those transfusions performed for bleeding, only 94 out of 151 platelet transfusions (62.3%) resulted in resolution of bleeding within 24 hours. Of these transfusions that resulted in the cessation of bleeding, fresh frozen plasma (FFP) was concurrently transfused 29.8% of the time.
The number and volume of platelet transfusions were not different between infants who survived and those who died (Table 3) . Although not statistically significant, infants that died received a higher number and volume of platelet transfusions. Post hoc adjustments for indomethacin treatment did not change the significance of these findings. Morbidity (short bowel syndrome and/or cholestasis), however, was greater with a higher number and a higher volume of platelet transfusions (Table 4 ). To correct for the possibility that some patients who died may have died before they could develop short bowel syndrome or cholestasis, we repeated our analyses on the subgroup of survivors and still found significant correlations between short bowel syndrome/cholestasis and a higher number or volume of platelet transfusions.
SIGNIFICANCE
Our study did not find a benefit of empiric platelet transfusion in patients with NEC with thrombocytopenia. This is not remarkable, as others have had similar experiences with platelet transfusions in premature infants. Andrew et al. 8 found that empiric platelet transfusions to maintain platelet counts >150,000/mm 3 did not decrease the incidence or extent of IVH in premature infants when compared to control infants whose platelet count was maintained > 50,000/mm 3 . Garcia et al. 11 found that one or more platelet transfusions may actually increase the mortality risk for VLBW infants with NEC. 11 Although we did not find a change in mortality associated with platelet transfusions, we did find increased morbidity associated with a higher number of platelet transfusions. Since there is no proven consistent benefit to platelet transfusions in neonates with NEC, there is wide variation in practices across the country at various neonatal units with regard to indications for platelet transfusions. 24 The two categories of indications for platelet transfusions in light of thrombocytopenia have traditionally been to stop bleeding or to prevent the occurrence of bleeding, particularly for invasive procedures. In our study, 62% of study infants with active bleeding treated with platelet transfusions had a resolution of bleeding; however, no obvious benefit of platelet transfusions was noted in thrombocytopenic infants with NEC transfused for other indications. These findings are not remarkable considering the limited data supporting the clinical benefit of increasing platelet counts prior to an invasive procedure or simply to achieve higher platelet counts in ill infants with thrombocythemia. 2, 8, 9, 11 Furthermore, the assumed benefit of platelet transfusions in resolving bleeding may be overestimated in our study in view of the fact that FFP was administered concurrently to 29.8% of patients with active bleeding. As prothrombin and partial prothrombin time are not routinely checked in our patients because of the volume of blood needed for their estimation (1.5 to 2 ml of blood), it is possible that other coagulation abnormalities existed in the sick, bleeding patients.
The lack of a clear benefit of platelet transfusion in maintaining a certain platelet level in NEC may not be surprising. Many studies implicate PAF in the pathogenesis of bowel necrosis and thrombocytopenia in NEC. 18, 19 PAF is a phospholipid produced by inflammatory cells, endothelial cells, platelets, and intestinal bacteria. 19, 25, 26 Injection of PAF or the injection of lipopolysacharides, a toxic product of bacteria that induces production of PAF, can induce shock and intestinal necrosis in rats and thrombocytopenia in human volunteers. 18, 26, 27 In the presence of inflammation, infection, or hypoxia, PAF is induced and subsequently augments activation of inflammatory neutrophils, production of reactive oxygen radicals, and production of tumor necrosis factor -all of which contribute to bowel injury and necrosis. [18] [19] [20] [21] 25 In our study, we found that an increased number and volume of platelet transfusions were associated with increased morbidity. We theorize that bioactive substances, like the cytokine PAF, contained in platelet transfusions may contribute to ongoing consumption and entrapment in the gut circulation of platelets transfused, resulting not only in further thrombocytopenia and platelet transfusion, but also in ongoing inflammatory bowel injury that could result in short bowel syndrome/cholestasis. Supporting this argument is the observation that exclusive feeding of breast milk prior to the onset of NEC was associated with a lower incidence of short bowel syndrome and cholestasis. This is congruent with other reports that breast milk is associated with a decreased incidence of NEC. 28 As breast milk has high levels of PAF-acetylhydrolase, the enzyme that degrades PAF, investigators have speculated that breast milk-derived PAF-acetylhydrolase provides protection against the development of NEC. [29] [30] [31] Given our results, we speculate that the breast milk-derived PAFacetylhydrolase may have served to decrease PAF-induced gut necrosis, and thus short bowel syndrome/cholestasis; however, exclusive breast milk consumption was not associated with decreased mortality, which may have been the result of extraintestinal systemic complications.
As with other retrospective studies, our study has results that suggest hypotheses best tested by prospective studies. As infants with NEC and severe thrombocytopenia are usually sicker than those without thrombocytopenia 5, 7 and may inevitably receive platelet transfusions, the mortality data needs to be interpreted with caution. For example, we found that a higher percentage of infants who died had received indomethacin when compared to those who lived. Although it is theoretically possible that infants treated with indomethacin may have a higher incidence of NEC, we have not previously found an increased incidence of NEC in infants treated with indomethacin for symptomatic PDA when compared to those treated with surgical ligation only. 32 In addition, two recent metaanalyses did not demonstrate an increased incidence of NEC in patients treated with indomethacin. 33, 34 However, whether prior treatment with indomethacin alters the morbidity and/or mortality of infants who develop NEC has yet to be adequately explored.
